Hers and Tirzepatide: Dual-Agonist Basics and the Program Model

This piece sits within the PlexusDx Education Hub, our resource on GLP-1 science, weight-management protocols, and the genetic factors that underlie metabolic decisions. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx maintains no commercial relationship with Hers and earns no affiliate revenue from anything described below.

Tirzepatide behaves differently from the single-pathway GLP-1 drugs it is often grouped with, and that mechanism shapes how any program should be read. Here we look at how a Hers telehealth model approaches tirzepatide, how branded and compounded routes diverge, and the genetic terrain the prescription is written into. Balanced editorial framing, not a recommendation to buy. As of April 2026.

Tirzepatide as a dual GIP/GLP-1 agonist

Tirzepatide activates two incretin receptors, GIP and GLP-1, rather than the single GLP-1 target of semaglutide and liraglutide. That dual mechanism is what distinguishes it pharmacologically within the weight-management category. When a telehealth program references tirzepatide, it is referring to that molecule, which may reach a patient as an FDA-approved branded product or as a compounded preparation.

How Hers structures a telehealth prescription

Hers, a Hims & Hers Health brand, operates as subscription telehealth. The typical sequence is an intake questionnaire covering weight, history, and medications; a licensed clinician's review; a prescription routed to a retail or 503A compounding pharmacy depending on the product; and ongoing follow-up for titration and tolerability. Provider type and pharmacy partner vary by case. Current details and any listed pricing appear on Hers's official website.

Branded versus compounded tirzepatide

An FDA-approved tirzepatide product and a compounded tirzepatide preparation are not interchangeable in regulatory terms: the compounded version, prepared by a 503A pharmacy under prescription, is not itself FDA-approved. Which route a program uses affects how the medicine is supplied and described. Program pricing is published on the brand's own site; the wider telehealth GLP-1 market runs roughly $200 to $700+ monthly as of April 2026, with substantial variance.

The SURMOUNT evidence

Tirzepatide's weight-management evidence centers on the SURMOUNT program (The New England Journal of Medicine, 2022), with SURMOUNT-OSA (NEJM, 2024) examining obstructive sleep apnea. For comparison, semaglutide's STEP program appeared in NEJM in 2021. These trials used different endpoints and populations, and outcomes vary from person to person.

The genetic layer these programs leave out

A tirzepatide protocol does not account for the upstream genetic architecture that shapes how any GLP-1 compound behaves in a given body. Variants in FTO, the fat-mass and obesity-associated gene, along with GLP1R (the GLP-1 receptor gene that every GLP-1 compound targets), MC4R (a melanocortin receptor tied to satiety and energy balance), and TCF7L2 (a transcription factor linked to glucose homeostasis) describe the metabolic terrain a clinician is prescribing into. These are pathway-level signals. They do not predict response to any specific medication, but they map the biology beneath the decision, context a telehealth prescription on its own never captures.

PlexusDx provides semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What distinguishes the approach is that upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including FTO, GLP1R, MC4R, and TCF7L2 variants that shape baseline appetite-regulation and energy-balance biology. Pairing that profile with the protocol is the test before you invest approach, turning guesswork into an informed conversation with your healthcare provider.

Not affiliated: PlexusDx is not affiliated with Hers and holds no commercial relationship with the companies discussed in this article.

Related reading on PlexusDx: Alternatives For Zepbound, Buy Zepbound Online, Discount Zepbound, GLP 1 vs Zepbound.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, and this review compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: explore the Weight Management Protocols for semaglutide and tirzepatide paired with the genetic context most telehealth programs omit. Or begin upstream and take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions

How is tirzepatide different from semaglutide?

Tirzepatide activates two incretin receptors, GIP and GLP-1, while semaglutide targets GLP-1 alone. That dual mechanism is what sets tirzepatide apart pharmacologically. Both are studied for weight management, but through different trial programs with different endpoints and populations.

Is compounded tirzepatide FDA-approved?

A compounded tirzepatide preparation from a 503A pharmacy is not itself an FDA-approved product, unlike a branded tirzepatide pen. The molecule is the same, but the regulatory status and supply chain differ, so the two should not be treated as interchangeable.

Does the genetic test predict tirzepatide response?

No. The Precision Peptide Genetic Test does not predict how you will respond to tirzepatide. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that map baseline metabolic biology, offering upstream context that applies no matter which compound a clinician prescribes.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education